Table 2. Correlations between clinicopathologic factors and FGFR2/SPRY2.
| Characters | FGFR2 | P* | SPRY2 | P* | ||
|---|---|---|---|---|---|---|
| Low | High | Low | High | |||
| Gender | ||||||
| Male | 41 | 25 | 0.833 | 44 | 22 | 1.00 |
| Female | 25 | 13 | 26 | 12 | ||
| Age | ||||||
| < 60 | 13 | 9 | 0.628 | 17 | 5 | 0.314 |
| ≥ 60 | 53 | 29 | 53 | 29 | ||
| Tumor diameter (cm) | ||||||
| ≤ 5 | 19 | 12 | 0.825 | 20 | 11 | 0.820 |
| > 5 | 47 | 26 | 50 | 12 | ||
| Differentiation | ||||||
| Well + Moderate | 38 | 21 | 0.840 | 41 | 18 | 0.674 |
| Poor | 28 | 17 | 29 | 16 | ||
| Tumor invasion | ||||||
| T1 + T2 | 25 | 10 | 0.284 | 16 | 19 | 0.002 |
| T3 + T4 | 41 | 28 | 54 | 15 | ||
| Lymph node metastasis | ||||||
| No (N0) | 34 | 9 | 0.007 | 21 | 22 | 0.001 |
| Yes (N1/2/3) | 32 | 29 | 49 | 12 | ||
| Distant metastasis | ||||||
| M0 | 63 | 34 | 0.256 | 63 | 34 | 0.093 |
| M1 | 3 | 4 | 7 | 0 | ||
| TNM stage | ||||||
| I | 8 | 4 | 0.701 | 7 | 5 | 0.217 |
| II | 17 | 14 | 17 | 14 | ||
| III | 32 | 14 | 39 | 13 | ||
| IV | 6 | 3 | 7 | 2 | ||
| Lauren subtype | ||||||
| Intestinal | 43 | 15 | 0.031 | 35 | 23 | 0.096 |
| Diffuse | 16 | 18 | 24 | 10 | ||
| Mixed | 7 | 5 | 11 | 1 | ||
| Peritoneal dissemination | ||||||
| Yes | 64 | 38 | 0.532# | 68 | 34 | 1.00# |
| No | 2 | 0 | 2 | 0 | ||
| SPRY1 | ||||||
| low | 54 | 34 | 0.401 | 61 | 27 | 0.386 |
| high | 12 | 4 | 9 | 7 | ||
| SPRY2 | ||||||
| low | 39 | 31 | 0.029 | |||
| high | 27 | 7 | ||||
| SPRY3 | ||||||
| low | 63 | 36 | 1.00# | 66 | 33 | 1.00# |
| high | 3 | 2 | 4 | 1 | ||
| SPRY4 | ||||||
| low | 51 | 32 | 0.456 | 56 | 27 | 1.00 |
| high | 15 | 6 | 14 | 7 | ||
| FGFR2 | ||||||
| low | 39 | 27 | 0.029 | |||
| high | 31 | 7 | ||||
*
means calculated by Chi-square test; #means calculated by Fisher test.
Abbreviations: FGFR2 = fibroblast growth factor receptor 2, SPRY = sprouty.